Eli Lilly’s experimental weight-loss drug retatrutide, nicknamed the “Godzilla” of obesity treatments, has delivered striking results in late-stage trials. In people with obesity or overweight, the highest dose produced average weight loss of more than 28% over 80 weeks, roughly twice the typical results seen with semaglutide (the active ingredient in Ozempic and Wegovy) in earlier obesity studies.
The findings have generated significant interest because retatrutide works differently from current GLP-1 drugs. While Ozempic primarily targets one hormone pathway, this next-generation candidate activates three.